Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study-Reference-Cited by-同舟云学术

Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study

Published:2023-01 Issue:1 Volume:23 Page:68-77
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Cohen Adam D.^ORCID,Hari Parameswaran,Htut Myo,Berdeja Jesus G.^ORCID,Usmani Saad Z.,Madduri Deepu,Olyslager Yunsi,Goldberg Jenna D.,Schecter Jordan M.,Jackson Carolyn C.,Gries Katharine S.,Fastenau John M.,Valluri Satish,Deraedt William,Akram Muhammad,Crawford Rebecca^ORCID,Morrison Ross,Doward Lynda,Morgan Kate,Seldam Silene ten,Jakubowiak Andrzej,Jagannath Sundar^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference26 articles.

1. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update;Nijhof;Drugs,2018

2. Treatment Options for Triple-class Refractory Multiple Myeloma;Mikhael;Clin Lymphoma Myeloma Leuk,2020

3. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up;Dimopoulos;Hemasphere,2021

4. Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry;Jagannath;Clin Lymphoma Myeloma Leuk,2020

5. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy;Gandhi;Leukemia,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promoting patient-centered care in CAR-T therapy for hematologic malignancy: a qualitative meta-synthesis;Supportive Care in Cancer;2024-08-16

2. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma;Expert Opinion on Biological Therapy;2024-05-03

3. The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs;Pharmacological Research;2024-05

4. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy;Transplantation and Cellular Therapy;2024-01

5. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma;Cell Reports Medicine;2023-10